Award type :
Product Development Award
Product Development Award
Product type :
Therapeutics
Therapeutics
Award year :
2022
2022
Project start date :
09 / 30 / 2022
09 / 30 / 2022
Project end date :
01 / 21/ 2025
01 / 21/ 2025
Project duration (months) :
27
27
Development stage :
Phase 2
Phase 2
Target disease :
Malaria
Malaria
Region served :
World
World
Recipient organization / Country of funding recipient organization :
Merck KGaA / Germany
Merck KGaA / Germany
Collaborator(s) / Country :
Shin Poong Pharm. Co., Ltd. / Republic of Korea
Shin Poong Pharm. Co., Ltd. / Republic of Korea
Funding amount(KRW) :
4,410,509,937
4,410,509,937
A monthly fixed-dose combination of cabamiquine (M5717) and pyronaridine was evaluated for malaria prevention. Leveraging complementary mechanisms of blood-stage parasite killing, the regimen demonstrated dose-dependent protection against malaria in Phase 2 studies, with a favorable safety profile and no discontinuations due to adverse events. These results provided a strong proof-of-concept for further development as a preventive regimen, with next steps currently under evaluation.